<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>LEVERT | Oneil Sellers | Activity</title>
	<link>https://levertmusic.net/members/browhall7/activity/</link>
	<atom:link href="https://levertmusic.net/members/browhall7/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Oneil Sellers.</description>
	<lastBuildDate>Thu, 29 Oct 2026 23:12:18 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">c20bf6b9acc6cc8e17673ea658330b44</guid>
				<title>Oneil Sellers posted an update: Understanding the Landscape: Multiple Myeloma Lawsuits and [&#133;]</title>
				<link>https://levertmusic.net/activity/p/1331112/</link>
				<pubDate>Mon, 17 Aug 2026 16:44:58 +0000</pubDate>

									<content:encoded><![CDATA[<p>Understanding the Landscape: Multiple Myeloma Lawsuits and Patient Safety Concerns</p>
<p>Multiple myeloma, a cancer of plasma cells in the bone marrow, remains a severe medical diagnosis, though advancements in treatment have actually substantially improved survival rates over the past 20 years. As unique therapies like immunomodulatory drugs&hellip;<span class="activity-read-more" id="activity-read-more-1331112"><a href="https://levertmusic.net/activity/p/1331112/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">821eb9edcbdb3588caa8c4bcaf8abdcd</guid>
				<title>Oneil Sellers posted an update: Multiple Myeloma Class Action Lawsuit: What Patients Need to [&#133;]</title>
				<link>https://levertmusic.net/activity/p/1330912/</link>
				<pubDate>Mon, 17 Aug 2026 16:09:05 +0000</pubDate>

									<content:encoded><![CDATA[<p><strong>Multiple Myeloma Class Action Lawsuit: What Patients Need to Know</strong> </p>
<p><em>A helpful guide for anybody impacted by multiple myeloma who is thinking about&#8211; or merely curious about&#8211; joining a class‑action lawsuit.</em> </p>
<p>Intro</p>
<p>Multiple myeloma (MM) is a plasma‑cell malignancy that impacts approximately 34,000 new clients each year in the United Sta&hellip;<span class="activity-read-more" id="activity-read-more-1330912"><a href="https://levertmusic.net/activity/p/1330912/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">668ad849a16b506463b009b97e5c3d89</guid>
				<title>Oneil Sellers posted an update: Multiple Myeloma Class Action Lawsuit: What Patients Need to [&#133;]</title>
				<link>https://levertmusic.net/activity/p/1330771/</link>
				<pubDate>Mon, 17 Aug 2026 15:43:00 +0000</pubDate>

									<content:encoded><![CDATA[<p><strong>Multiple Myeloma Class Action Lawsuit: What Patients Need to Know</strong> </p>
<p><em>A helpful guide for anybody affected by multiple myeloma who is considering&#8211; or just curious about&#8211; joining a class‑action lawsuit.</em> </p>
<p>Introduction</p>
<p>Multiple myeloma (MM) is a plasma‑cell malignancy that affects roughly 34,000 new patients each year in the United Sta&hellip;<span class="activity-read-more" id="activity-read-more-1330771"><a href="https://levertmusic.net/activity/p/1330771/" rel="nofollow ugc">Read more</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">64cd2e4f78b012b10ef04197504b8d73</guid>
				<title>Oneil Sellers became a registered member</title>
				<link>https://levertmusic.net/activity/p/1330619/</link>
				<pubDate>Mon, 17 Aug 2026 15:19:31 +0000</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>